Biotech groups slam Malaysia, Canada and Korea in Special 301 comments

Trade associations Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization (BIO) have called for Malaysia to be placed on the US Trade Representative’s (USTR) watch list in its “2018 Special 301 Report”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

WHO and UN actions undermine IP and hurt innovation, warns PhRMA

18 March 2019 Supranational organisations such as the World Health Organization and the United Nations Development Program are promoting acts, policies and practices that prevent biopharmaceutical innovators from securing and maintaining patents.

Americas

PhRMA urges USTR to protect US innovation abroad

13 February 2017 The Pharmaceutical Research and Manufacturers of America has urged the US Trade Representative to protect US innovators abroad.

Africa

BIO welcomes ‘Special 301 Report’

29 April 2016 The Biotechnology Innovation Organization has welcomed the US Trade Representative’s “Special 301 Report”, which it said “aims to advance global IP rights in biotechnology in a number of constructive ways”.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Biotech groups slam Malaysia, Canada and Korea in Special 301 comments

More on this story

Editor's picks

Editor's picks

More features